In addition, several reports have indicated that alectinib exhibits excellent antitumor efficacy for CNS metastases in ALK+ NSCLC pts with or without prior ALKi treatment, including crizotinib and ceritinib [7, 8, 19, 20, 23–25]. This evidence concerns the gene ALK and non-small cell lung carcinoma.